We use cookies for a better user experience. Read our Privacy Policy

I Agree

Hospital Infection Therapeutics Market

Hospital Infection Therapeutics Market (Therapeutics - Anti-bacterial Drugs, Anti-fungal Drugs, Anti-viral Drugs; Infection - Hospital Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections, Other Hospital Infections) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Hospital Infection Therapeutics Market - Snapshot

Hospital-acquired infections are a highly prevalent adverse events in the health care industry. Presence of unhygienic conditions in and around hospitals along with improper sterilization techniques applied in these settings augments the prevalence of hospital-acquired infections in the low and middle income countries. The global hospital infection therapeutics market is characterized by increase in incidence of infections of resistance bacteria. The market is witnessing gradual rise in research and development activities to develop novel antibiotics, which are supported by government policies. Hence, the global hospital infection therapeutics market was valued at US$ 14.4 Bn in 2017 and is projected to expand at a significant CAGR of 2.4% from 2018 to 2026.

hospital infection therapeutics

Increase in the geriatric population which is more prone to hospital-acquired infections, significant patient population in developing countries demanding proper treatment, and investments by public and private players for R&D on anti-infective drugs against resistant bacteria are the major factors driving the global hospital infection therapeutics market. However, surge in the incidence of treatment-emergent resistance, significant investment required due to high attrition rate in clinical trials, and changing reimbursement policies are resulting in limited pipeline drugs. This is likely to restrain the global hospital infection therapeutics market during the forecast period. Investment in R&D on non-antibiotic treatment options and partnerships for co-development and commercialization of anti-infective agents are expected to fuel the growth of the global hospital infection therapeutics market.

In terms of therapeutics, the global hospital infection therapeutics market has been classified into anti-bacterial drugs, anti-fungal drugs, anti-viral drugs, and others. The others segment comprises drug classes such as anti-parasitic drugs. The anti-bacterial drugs segment has been divided into cell wall synthesis inhibitors, protein synthesis inhibitors, and others. The cell wall synthesis inhibitors sub-segment comprises cephalosporins, carbapenems, vancomycin, and others. The protein synthesis inhibitors sub-segment comprises aminoglycosides, linezolid, tigecycline, and others. The anti-fungal drugs segment has been categorized into Caspofungin, Amphotericin B, and others. The others sub-segment includes Triazoles, fluconazole, voriconazole, and others. The anti-bacterial drugs segment is projected to dominate the market during the forecast period owing to an increase in initiatives such as the Global Action Plan on Antimicrobial Resistance by WHO and Drive AB by Innovative Medicines Initiative, and presence of key companies such as Merck & Co., Inc. and Pfizer, Inc. engaged in the manufacture of anti-bacterial drugs. These initiatives are aimed at increasing research and development activities to overcome drug resistance. The relatively stable growth rate of the segment is attributed to increase in antibiotic resistance of bacteria and limited pipeline drug candidates. The anti-viral drugs segment is anticipated to register above average growth rate owing to rise in the prevalence of severe bloodstream infections and increase in focus on research and development to overcome the risk of virus structural mutations. Based on infection, the market has been divided into hospital acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections, and other hospital infections. The hospital acquired pneumonia segment is likely to dominate the market during the forecast period with above average growth rate, followed by surgical site infections, due to increase in incidence rate of respiratory infections among the geriatric population, comparatively above average cost of therapy, and prevalence of multidrug-resistant micro-organisms in ICU units.

In terms of region, the global hospital infection therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe accounted for major share of 39% of the global market in terms of revenue in 2017. North America was another major market for hospital infection therapeutics in 2017. Relatively high cost of treatment compared to that in emerging countries, developed health care infrastructure, and larger reimbursement coverage which provides assured investment return for new market entrants contribute to the significant share of the two regions. However, high growth rate of the pharmaceutical industry in India and China and investment by global investors in China for development of novel treatment approaches for hospital-acquired infections are expected to propel the hospital infection therapeutics market in Asia Pacific.

Major players operating in the global hospital infection therapeutics market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Allergan plc, Sanofi S.A., Gilead Sciences, Inc., Basilea Pharmaceutica Ltd., and Bristol-Myers Squibb Company.

The global hospital infection therapeutics market has been segmented as follows:

Therapeutics

  • Anti-bacterial Drugs
  • Anti-fungal Drugs
  • Anti-viral Drugs
  • Others

Infection

  • Hospital Acquired Pneumonia
  • Urinary Tract Infections
  • Gastrointestinal Disorders
  • Bloodstream Infections
  • Surgical Site Infections
  • Other Hospital Infections

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Hospital Infection Therapeutics Market

    4. Market Overview
         4.1. Introduction
                4.1.1. Therapeutics Definition
                4.1.2. Industry Evolution / Developments
         4.2. Overview
         4.3. Market Dynamics
                4.3.1. Drivers
                4.3.2. Restraints
                4.3.3. Opportunities
         4.4. Global Hospital Infection Therapeutics Market Analysis and Forecast, 2016–2026
                4.4.1. Market Revenue Projections (US$ Mn)
                4.4.2. Market Volume/Unit Shipments Projections
         4.5. Porter’s Five Force Analysis

    5. Market Outlook
         5.1.Regulatory Scenario by Region/globally
         5.2.Pipeline Analysis
         5.3.Reimbursement Scenario by Region/globally
         5.4.Disease Prevalence & Incidence Rate globally with key countries
         5.5.Healthcare Industry Overview
         5.6.Value Chain Analysis

    6. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Therapeutics
         6.1. Introduction & Definition
         6.2. Key Findings / Developments
         6.3. Market Forecast, by Therapeutics, 2016–2026
                6.3.1. Antibacterial Drugs
                         6.3.1.1. Cell Wall Synthesis Inhibitors
                         6.3.1.2. Protein Synthesis Inhibitors
                         6.3.1.3. Others
                6.3.2. Antifungal Drugs
                         6.3.2.1. Caspofungin
                         6.3.2.2. Amphotericin B
                         6.3.2.3. Others
                6.3.3. Antiviral Drugs
                6.3.4. Others
         6.4. Market Attractiveness, by Therapeutics

    7. Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Infection
         7.1. Introduction & Definition
         7.2. Key Findings / Developments
         7.3. Market Forecast, by Infection, 2016–2026
                7.3.1. Hospital Acquired Pneumonia
                7.3.2. Urinary Tract Infections
                7.3.3. Gastrointestinal Disorders
                7.3.4. Bloodstream Infections
                7.3.5. Surgical Site Infections
                7.3.6. Other Hospital Infections
         7.4. Market Attractiveness, by Infection

    8. Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Region
         8.1. Key Findings
         8.2. Market Forecast, by Region
                8.2.1. North America
                8.2.2. Europe
                8.2.3. Asia Pacific
                8.2.4. Latin America
                8.2.5. Middle East & Africa
         8.3. Market Attractiveness, by Country/Region

    9. North America Hospital Infection Therapeutics Market Analysis and Forecast
         9.1. Introduction
                9.1.1. Key Findings
         9.2. Market Forecast, by Therapeutics, 2016–2026
                9.2.1. Antibacterial Drugs
                         9.2.1.1. Cell Wall Synthesis Inhibitors
                         9.2.1.2. Protein Synthesis Inhibitors
                         9.2.1.3. Others
                9.2.2. Antifungal Drugs
                         9.2.2.1. Caspofungin
                         9.2.2.2. Amphotericin B
                         9.2.2.3. Others
                9.2.3. Antiviral Drugs
                9.2.4. Others
         9.3. Market Forecast, by Infection, 2016–2026
                9.3.1. Hospital Acquired Pneumonia
                9.3.2. Urinary Tract Infections
                9.3.3. Gastrointestinal Disorders
                9.3.4. Bloodstream Infections
                9.3.5. Surgical Site Infections
                9.3.6. Other Hospital Infections
         9.4. Market Forecast, by Country, 2016–2026
                9.4.1. U.S.
                9.4.2. Canada
         9.5. Market Attractiveness Analysis
                9.5.1. By Therapeutics
                9.5.2. By Infection
                9.5.3. By Country

    10. Europe Hospital Infection Therapeutics Market Analysis and Forecast
         10.1. Introduction
                10.1.1. Key Findings
         10.2. Market Forecast, by Therapeutics, 2016–2026
                10.2.1. Antibacterial Drugs
                         10.2.1.1. Cell Wall Synthesis Inhibitors
                         10.2.1.2. Protein Synthesis Inhibitors
                         10.2.1.3. Others
                10.2.2. Antifungal Drugs
                         10.2.2.1. Caspofungin
                         10.2.2.2. Amphotericin B
                         10.2.2.3. Others
                10.2.3. Antiviral Drugs
                10.2.4. Others
         10.3. Market Forecast, by Infection, 2016–2026
                10.3.1. Hospital Acquired Pneumonia
                10.3.2. Urinary Tract Infections
                10.3.3. Gastrointestinal Disorders
                10.3.4. Bloodstream Infections
                10.3.5. Surgical Site Infections
                10.3.6. Other Hospital Infections
         10.4. Market Forecast, by Country/Sub-region, 2016–2026
                10.4.1. Germany
                10.4.2. U.K.
                10.4.3. France
                10.4.4. Spain
                10.4.5. Italy
                10.4.6. Russia
                10.4.7. Rest of Europe
         10.5. Market Attractiveness Analysis
                10.5.1. By Therapeutics
                10.5.2. By Infection
                10.5.3. By Country/Sub-region

    11. Asia Pacific Hospital Infection Therapeutics Market Analysis and Forecast
         11.1.Introduction
                11.1.1. Key Findings
         11.2.Market Forecast, by Therapeutics, 2016–2026
                11.2.1. Antibacterial Drugs
                         11.2.1.1. Cell Wall Synthesis Inhibitors
                         11.2.1.2. Protein Synthesis Inhibitors
                         11.2.1.3. Others
                11.2.2. Antifungal Drugs
                         11.2.2.1. Caspofungin
                         11.2.2.2. Amphotericin B
                         11.2.2.3. Others
                11.2.3. Antiviral Drugs
                11.2.4. Others
         11.3.Market Forecast, by Infection, 2016–2026
                11.3.1. Hospital Acquired Pneumonia
                11.3.2. Urinary Tract Infections
                11.3.3. Gastrointestinal Disorders
                11.3.4. Bloodstream Infections
                11.3.5. Surgical Site Infections
                11.3.6. Other Hospital Infections
         11.4.Market Forecast, by Country/Sub-region, 2016–2026
                11.4.1. China
                11.4.2. Japan
                11.4.3. India
                11.4.4. Australia & New Zealand
                11.4.5. Rest of Asia Pacific
         11.5.Market Attractiveness Analysis
                11.5.1. By Therapeutics
                11.5.2. By Infection
                11.5.3. By Country/Sub-region

    12. Latin America Hospital Infection Therapeutics Market Analysis and Forecast
         12.1.Introduction
                12.1.1. Key Findings
         12.2.Market Forecast, by Therapeutics, 2016–2026
                12.2.1. Antibacterial Drugs
                         12.2.1.1. Cell Wall Synthesis Inhibitors
                         12.2.1.2. Protein Synthesis Inhibitors
                         12.2.1.3. Others
                12.2.2. Antifungal Drugs
                         12.2.2.1. Caspofungin
                         12.2.2.2. Amphotericin B
                         12.2.2.3. Others
                12.2.3. Antiviral Drugs
                12.2.4. Others
         12.3.Market Forecast, by Infection, 2016–2026
                12.3.1. Hospital Acquired Pneumonia
                12.3.2. Urinary Tract Infections
                12.3.3. Gastrointestinal Disorders
                12.3.4. Bloodstream Infections
                12.3.5. Surgical Site Infections
                12.3.6. Other Hospital Infections
         12.4.Market Forecast, by Country/Sub-region, 2016–2026
                12.4.1. Brazil
                12.4.2. Mexico
                12.4.3. Rest of Latin America
         12.5.Market Attractiveness Analysis
                12.5.1. By Therapeutics
                12.5.2. By Infection
                12.5.3. By Country/Sub-region

    13. Middle East & Africa Hospital Infection Therapeutics Market Analysis and Forecast
         13.1.Introduction
                13.1.1. Key Findings
         13.2.Market Forecast, by Therapeutics, 2016–2026
                13.2.1. Antibacterial Drugs
                         13.2.1.1. Cell Wall Synthesis Inhibitors
                         13.2.1.2. Protein Synthesis Inhibitors
                         13.2.1.3. Others
                13.2.2. Antifungal Drugs
                         13.2.2.1. Caspofungin
                         13.2.2.2. Amphotericin B
                         13.2.2.3. Others
                13.2.3. Antiviral Drugs
                13.2.4. Others
         13.3.Market Forecast, by Infection, 2016–2026
                13.3.1. Hospital Acquired Pneumonia
                13.3.2. Urinary Tract Infections
                13.3.3. Gastrointestinal Disorders
                13.3.4. Bloodstream Infections
                13.3.5. Surgical Site Infections
                13.3.6. Other Hospital Infections
         13.4.Market Forecast, by Country/Sub-region, 2016–2026
                13.4.1. GCC Countries
                13.4.2. South Africa
                13.4.3. Israel
                13.4.4. Rest of Middle East & Africa
         13.5.Market Attractiveness Analysis
                13.5.1. By Therapeutics
                13.5.2. By Infection
                13.5.3. By Country/Sub-region

    14. Competition Landscape
         14.1.Market Player – Competition Matrix (By Tier and Size of companies)
         14.2.Market Share Analysis By Company (2017)
         14.3.Market Footprint Analysis
         14.4. Competitive Business Strategies
         14.5. Company Profiles
                14.5.1. Allergan
                         14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.1.2. Product Portfolio
                         14.5.1.3. SWOT Analysis
                         14.5.1.4. Strategic Overview
                         14.5.1.5. Financial Overview
                14.5.2. AstraZeneca
                         14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.2.2. Product Portfolio
                         14.5.2.3. SWOT Analysis
                         14.5.2.4. Strategic Overview
                         14.5.2.5. Financial Overview
                14.5.3. Basilea Pharmaceutica Ltd.
                         14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.3.2. Product Portfolio
                         14.5.3.3. SWOT Analysis
                         14.5.3.4. Strategic Overview
                         14.5.3.5. Financial Overview
                14.5.4. Bayer AG
                         14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.4.2. Product Portfolio
                         14.5.4.3. SWOT Analysis
                         14.5.4.4. Strategic Overview
                         14.5.4.5. Financial Overview
                14.5.5. Bristol-Myers Squibb Company
                         14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.5.2. Product Portfolio
                         14.5.5.3. SWOT Analysis
                         14.5.5.4. Strategic Overview
                         14.5.5.5. Financial Overview
                14.5.6. F. Hoffman-La Roche Ltd.
                         14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.6.2. Product Portfolio
                         14.5.6.3. SWOT Analysis
                         14.5.6.4. Strategic Overview
                         14.5.6.5. Financial Overview
                14.5.7. GlaxoSmithKline plc.
                         14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.7.2. Product Portfolio
                         14.5.7.3. SWOT Analysis
                         14.5.7.4. Strategic Overview
                         14.5.7.5. Financial Overview
                14.5.8. Johnson & Johnson Services, Inc.
                         14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.8.2. Product Portfolio
                         14.5.8.3. SWOT Analysis
                         14.5.8.4. Strategic Overview
                         14.5.8.5. Financial Overview
                14.5.9. Merck & Co., Inc.
                         14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.9.2. Product Portfolio
                         14.5.9.3. SWOT Analysis
                         14.5.9.4. Strategic Overview
                         14.5.9.5. Financial Overview
                14.5.10. Pfizer Inc.
                         14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.10.2. Product Portfolio
                         14.5.10.3. SWOT Analysis
                         14.5.10.4. Strategic Overview
                         14.5.10.5. Financial Overview
                14.5.11. Sanofi
                         14.5.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.11.2. Product Portfolio
                         14.5.11.3. SWOT Analysis
                         14.5.11.4. Strategic Overview
                         14.5.11.5. Financial Overview

    List of Tables

    Table 01 WHO priority list and drug candidates in pre-clinical and clinical development
    Table 02 Pipeline Analysis of Hospital Infection Therapeutics (1/5)
    Table 03 Pipeline Analysis of Hospital Infection Therapeutics (2/5)
    Table 04 Pipeline Analysis of Hospital Infection Therapeutics (3/5)
    Table 05 Pipeline Analysis of Hospital Infection Therapeutics (4/5)
    Table 06 Pipeline Analysis of Hospital Infection Therapeutics (5/5)
    Table 07 Disease Prevalence & Incidence Rate Globally, by Key Countries
    Table 08 Healthcare Industry Overview
    Table 09 Incidence Rate (per 100,000 population) of S. aureus bacteremia, U.K., 2013 (1/2)
    Table 10 Table: Incidence Rate (per 100,000 population) of S. aureus bacteremia, U.K., 2013 (2/2)
    Table 11 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
    Table 12 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-bacterial Drugs, 2016–2026
    Table 13 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-fungal Drugs, 2016–2026
    Table 14 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
    Table 15 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
    Table 16 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
    Table 17 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
    Table 18 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-bacterial Drugs, 2016–2026
    Table 19 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-fungal Drugs, 2016–2026
    Table 20 North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
    Table 21 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 22 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
    Table 23 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-bacterial Drugs, 2016–2026
    Table 24 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-fungal Drugs, 2016–2026
    Table 25 Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
    Table 26 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 27 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
    Table 28 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-bacterial Drugs, 2016–2026
    Table 29 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics - Anti-fungal Drugs, 2016–2026
    Table 30 Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
    Table 31 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 32 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
    Table 33 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics: Anti-bacterial Drugs, 2016–2026
    Table 34 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics: Anti-fungal Drugs, 2016–2026
    Table 35 Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026
    Table 36 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 37 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2016–2026
    Table 38 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Anti-bacterial Drugs, 2016–2026
    Table 39 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Anti-fungal Drugs, 2016–2026
    Table 40 Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2016–2026

    List of Figures

     

    Figure 01 Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
    Figure 02 Global Hospital Infection Therapeutics Market Value Share (%), by Therapeutics (2017)
    Figure 03 Global Hospital Infection Therapeutics Market Value Share (%), by Region (2017)
    Figure 04 Global Hospital Infection Therapeutics Market Value Share (%), by Infection (2017)
    Figure 05 Percentage Distribution of Population Aged 65 and Over, by Region: 2015
    Figure 06 Percentage Distribution of Population Aged 65 and Over, by Region: 2050
    Figure 07 Regulatory Approval Process - U.S.
    Figure 08 Regulatory Approval Process - Europe
    Figure 09 Regulatory Approval Process - Japan
    Figure 10 Global Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
    Figure 11 Global Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
    Figure 12 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-bacterial Drugs, 2016–2026
    Figure 13 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-fungal Drugs, 2016–2026
    Figure 14 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-viral Drugs, 2016–2026
    Figure 15 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
    Figure 16 Global Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
    Figure 17 Global Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
    Figure 18 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Acquired Pneumonia, 2016–2026
    Figure 19 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Urinary Tract Infections, 2016–2026
    Figure 20 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Gastrointestinal Disorders, 2016–2026
    Figure 21 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Bloodstream Infections, 2016–2026
    Figure 22 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Surgical Site Infections, 2016–2026
    Figure 23 Global Hospital Infection Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Other Hospital Infections, 2016–2026
    Figure 24 Global Hospital Infection Therapeutics Market Value Share (%), by Region, 2017 and 2026
    Figure 25 Global Hospital Infection Therapeutics Market Attractiveness, by Region, 2018–2026
    Figure 26 North America Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 27 North America Hospital Infection Therapeutics Market Value Share (%), by Country, 2017 and 2026
    Figure 28 North America Hospital Infection Therapeutics Market Attractiveness, by Country, 2018–2026
    Figure 29 North America Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
    Figure 30 North America Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
    Figure 31 North America Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
    Figure 32 North America Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
    Figure 33 Europe Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 34 Europe Hospital Infection Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
    Figure 35 Europe Hospital Infection Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 36 Europe Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
    Figure 37 Europe Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
    Figure 38 Europe Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
    Figure 39 Europe Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
    Figure 40 Asia Pacific Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 41 Asia Pacific Hospital Infection Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
    Figure 42 Asia Pacific Hospital Infection Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 43 Asia Pacific Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
    Figure 44 Asia Pacific Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
    Figure 45 Asia Pacific Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
    Figure 46 Asia Pacific Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
    Figure 47 Latin America Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 48 Latin America Hospital Infection Therapeutics Market Value Share (%), by Country/Sub-region,
    Figure 49 Latin America Hospital Infection Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 50 Latin America Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
    Figure 51 Latin America Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
    Figure 52 Latin America Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
    Figure 53 Latin America Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
    Figure 54 Middle East & Africa Hospital Infection Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 55 Middle East & Africa Hospital Infection Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
    Figure 56 Middle East & Africa Hospital Infection Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 57 Middle East & Africa Hospital Infection Therapeutics Market Value Share (%), by Therapeutics, 2017 and 2026
    Figure 58 Middle East & Africa Hospital Infection Therapeutics Market Attractiveness, by Therapeutics, 2018–2026
    Figure 59 Middle East & Africa Hospital Infection Therapeutics Market Value Share (%), by Infection, 2017 and 2026
    Figure 60 Middle East & Africa Hospital Infection Therapeutics Market Attractiveness, by Infection, 2018–2026
    Figure 61 Global Hospital Infection Therapeutics Market Share, by Company, 2017
    Figure 62 Competition Matrix (1/2)
    Figure 63 Competition Matrix (2/2)

Google translate

Copyright © Transparency Market Research, Inc. All Rights reserved